PRESS RELEASE published on 07/01/2024 at 06:50, 2 years 1 month ago Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2) Formycon receives FDA approval for FYB203/AHZANTIVE(R) (aflibercept-mrbb), a biosimilar to Eylea(R). The approval highlights Formycon's expertise and commitment to providing effective and affordable biosimilar therapies for retinal diseases. FDA Approval Biosimilar Formycon Eylea Retinal Diseases
BRIEF published on 06/28/2024 at 23:55, 2 years 1 month ago FDA Approves Biosimilar FYB203/AHZANTIVE® for Retinal Diseases FDA Approval Biosimilar Eylea Retinal Diseases Treatment Approval
BRIEF published on 06/28/2024 at 23:55, 2 years 1 month ago La FDA approuve le biosimilaire FYB203/AHZANTIVE® pour les maladies rétiniennes Approbation De La FDA Biosimilaire Eylea Maladies De La Rétine Approbation Du Traitement
PRESS RELEASE published on 06/28/2024 at 23:50, 2 years 1 month ago EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb) FDA grants approval for Eylea biosimilar FYB203/AHZANTIVE by Formycon AG and Klinge Biopharma GmbH. Biosimilar approved for nAMD and other retinal diseases FDA Approval Retinal Diseases Eylea Biosimilar FYB203/AHZANTIVE Neovascular Age-Related Macular Degeneration
BRIEF published on 06/13/2024 at 15:35, 2 years 2 months ago Formycon Announces AGM Results and Board Changes Shareholders 2023 Financial Year Supervisory Board AGM Formycon
BRIEF published on 06/13/2024 at 15:35, 2 years 2 months ago Formycon annonce les résultats de l'AGA et les changements au conseil d'administration Actionnaires Exercice 2023 Conseil De Surveillance AGA Formycon
PRESS RELEASE published on 06/13/2024 at 15:30, 2 years 2 months ago Formycon reports on the results of the Annual General Meeting Formycon AG reports on the results of its Annual General Meeting, including approvals of agenda items, new Supervisory Board members, and election of new Chairman Annual General Meeting Shareholders Supervisory Board Formycon AG Biosimilars
BRIEF published on 06/13/2024 at 10:46, 2 years 2 months ago First Berlin Equity Research Lowers Price Target for Formycon AG to €80 First Berlin Equity Research Buy Recommendation Formycon AG FYB202 Stelara
BRIEF published on 06/13/2024 at 10:46, 2 years 2 months ago First Berlin Equity Research abaisse son objectif de cours pour Formycon AG à 80 € Formycon AG Recommandation D'achat FYB202 Première Recherche Sur Les Actions À Berlin Stelara
PRESS RELEASE published on 06/13/2024 at 10:41, 2 years 2 months ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research GmbH reaffirms Buy recommendation for Formycon AG and lowers price target to €80 amid expected launch of lucrative biosimilar FYB202. Analyst Simon Scholes provides insights on Formycon's future prospects and market dynamics Stock Market Analysis Buy Recommendation Formycon AG First Berlin Equity Research GmbH Biosimilar
Published on 08/17/2026 at 15:00, 4 hours 5 minutes ago Norsemont Appoints Ariel Tepperman to Its Board
Published on 08/17/2026 at 14:30, 4 hours 35 minutes ago Alset AI Completes Sale of 9.9% Interest in Lyken AI Computing to FingerMotion
Published on 08/17/2026 at 14:00, 5 hours 5 minutes ago FaZe Esports, a GameSquare Company, Wins Rainbow Six Championship at 2026 Esports World Cup
Published on 08/17/2026 at 14:00, 5 hours 5 minutes ago Orogen Royalties and Aurum Discovery form Generative Alliance in Norway
Published on 08/17/2026 at 13:00, 6 hours 5 minutes ago Eagle Plains Samples up to 269g/t Au at the Pine Channel Gold Project, Saskatchewan
Published on 08/17/2026 at 17:50, 1 hour 15 minutes ago EvoNext Holdings SA confirms advanced discussions on a reverse merger with Ascend Sport Technology AG
Published on 08/17/2026 at 17:45, 1 hour 20 minutes ago Press release: Information on Leonteq's shareholder base
Published on 08/17/2026 at 17:40, 1 hour 25 minutes ago VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31.07.26.
Published on 08/17/2026 at 17:40, 1 hour 25 minutes ago Infotel : Déclaration des transactions sur actions propres réalisées du 10 au 14 août 2026 dans le cadre du programme de rachat d’actions.
Published on 08/17/2026 at 14:19, 4 hours 46 minutes ago Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Published on 08/17/2026 at 09:59, 9 hours 6 minutes ago 260817 BENETEAU Transaction sur actions propres